Changjiang Zhenchang, deputy bureau of Fujian Food and Drug Administration, stated in his speech that Fujian Province is fully promoting the development of the province's pharmaceutical industry. According to the province's judgment on the future development trend of the pharmaceutical industry and the requirements of target development, an industrial development plan was formulated, and the phased goals were clarified. Promote the fundamental transformation of the growth mode of the pharmaceutical industry, and make the pharmaceutical industry in Fujian Province bigger and stronger.
Among the top 100 pharmaceutical industry lists issued by the conference, Tasly Group, Modification Pharmaceutical, Harbin Pharmaceutical Group, CSPC, Buchang Group, Furen Pharmaceutical, China Resources Pharmaceutical, Yuekang Pharmaceutical, Wanxi Pharmaceutical, Simcere Pharmaceuticals, Qilu Pharmaceuticals, Shanghai Pharmaceuticals Group, Hengrui Pharmaceuticals, Bikang Pharmaceuticals, North China Pharmaceuticals Group, Chenxin Pharmaceuticals, Luye Pharmaceuticals, Zhongsheng Pharmaceuticals, Kangmei Pharmaceuticals, Li Shizhen Pharmaceuticals Group, Zhongzhi Pharmaceuticals and other companies obtained Won the honor of one of the top 100 enterprises in China's pharmaceutical industry.
It is understood that the selection was launched in early 2012, and the time span is 2011. Through intensive surveys of pharmaceutical companies registered in China, the list of the top 100 companies is based on the annual sales revenue of the pharmaceutical industry as a statistical indicator.
The list shows that the overall scale of the top 100 pharmaceutical industries in 2011 continued to increase, with a total sales revenue of 552.416 billion yuan, a year-on-year increase of 27.01%, and the growth rate was 1.19 percentage points lower than the same period in 2010 (28.20%).
Among the top 100 pharmaceutical companies in the pharmaceutical industry, there are 11 companies with a scale of more than 10 billion yuan, 23 companies with a scale of 5 billion to 10 billion yuan (not including, the same below), and 51 companies with a scale of 2 billion to 5 billion yuan. There are 15 enterprises with a scale of less than 2 billion yuan. The rapid development of medium-sized enterprises is the continuous driving force for the top 100 belts. The number of enterprises with scales between 2 billion and 5 billion yuan and 5 billion and 10 billion yuan has increased by 3 and 2 respectively compared with 2010.
According to the data from the list, the number of pharmaceutical groups with more than 10 billion in my country in 2011 more than doubled compared with 2010, and the embryonic form of large pharmaceutical groups has taken shape. Among them, China Resources Pharmaceutical Group first appeared at the top of the list in the name of the group. In 2011, China Resources Pharmaceutical achieved a turnover of 67.9 billion Hong Kong dollars, an operating profit of 4.87 billion Hong Kong dollars, and total assets of 61.9 billion Hong Kong dollars.
Analysts believe that the main reason for China Resources Pharmaceutical's top ranking is the expansion of its scale through mergers and reorganizations. In addition, the conference issued the Top 100 Innovation List, Jiangsu Hengrui Pharmaceutical Co., Ltd., Simcere Pharmaceutical Co., Ltd., Tianjin Tasly Group Co., Ltd., CSPC Group Co., Ltd., Qilu Pharmaceutical Co., Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Dongyang Sunshine Pharmaceutical Co., Ltd., Jiangsu Kangyuan Group Co., Ltd., Shandong Luye Pharmaceutical Group Co., Ltd., Chenxin Pharmaceutical Co., Ltd. and other enterprises have been awarded this honor.
At a time when global cooperation has become the key word of innovation, pharmaceutical industry companies promote the efficient integration of R&D resources through alliances, and promote the orderly integration of supervision and industry. Initiated by the "Pharmaceutical Economic News" of the Southern Institute, the China Pharmaceutical Innovation Enterprise Alliance, which is actively responded to by more than 30 domestic top 100 pharmaceutical companies, was also grandly held at the opening ceremony of the China Pharmaceutical Top 100 Association.
Disclosure of the ranking of innovative pharmaceutical companies for the first time
In addition to the top 100 pharmaceutical industry list, the Southern Institute of Pharmaceutical Economics also announced for the first time the top ten most innovative pharmaceutical companies in China. Hengrui, Simcere and Tasly ranked the top three.
Tao Jianhong believes that innovative companies can be divided into three echelons. The first is pioneering original pharmaceutical companies, such as Simcere Pharmaceuticals and Hengrui Pharmaceuticals, which successfully declared 1.1 new drugs in 2011; the second is the backbone of high-efficiency learning. Strengths, such as Livzon Pharmaceutical’s active deployment in the field of monoclonal antibodies, Hisun Pharmaceuticals and Huahai Pharmaceuticals in the field of specialty APIs; the third is integrated innovation, many Chinese medicine companies in the top 100 have outstanding performance, such as Wuhan Jian People in the field of pediatric medicine increase the development of new dosage forms and new varieties, and Guizhou Bailing's strength in the field of ethnic medicine.
Hengrui Medicine is known as "the company with the most new drug research and development by A-share listed companies". Despite its low-key style, the company's 2011 annual report still cannot stop its research and development edge: a new class of drug Irecoxib has been approved for listing, and it is declared for SH Six clinical projects such as R 1258, production projects such as febuxostat tablets, the innovative drug apatinib completed phase III clinical research of lung cancer; the approval of irinotecan injection to be marketed in the United States is a milestone.
It is reported that in 2010 and 2012, Simcere Pharmaceutical Co., Ltd., a total of eight Class 1 innovative drugs entered and will soon enter the clinical research stage. This is the first company among more than 4000 pharmaceutical companies in China to make such progress; in 2011, Simcere Innovative drugs for the treatment of stroke have completed Phase I clinical trials in Australia. This is also the first innovative drug injection from China to carry out clinical research in Western countries. The relevant person in charge of Simcere Pharmaceuticals told reporters that Simcere Pharmaceuticals will continue to increase investment in new drug research and development, and the investment ratio will gradually increase to 10% of sales revenue. At the same time, it will continue to "independent R&D and joint development with internationally renowned R&D platforms". The research and development model. The direction of R&D and innovation will still focus on the treatment of diseases with high morbidity or mortality and more effective drug demand. Therefore, the R&D field will continue to focus on anti-tumor, cardiovascular and cerebrovascular, anti-infection, anti-inflammatory and analgesic, etc. Disease treatment field.
Accelerating the pace of capitalization operations
The Economic Research Office of the Southern Institute of Pharmaceutical Economics analyzed the structure of the top 100 pharmaceutical industries in 2011 and pointed out that in 2011, the pace of capitalization of pharmaceutical enterprises has accelerated.
With the maturity of my country's capital market and the activity of industrial capital, more and more companies have entered the list of listed companies. In 2011, there were 23 newly listed pharmaceutical companies, mainly 7 companies on the small and medium-sized enterprise board and 16 companies on the ChiNext. Among the companies on the list of the top 100 pharmaceutical companies in 2011, there are 70 listed companies (including overseas listings, the same below), and 929 subsidiaries are included in the scope of consolidation by listed companies.
However, the top 100 list shows that the utilization of corporate funds has decreased. In 2011, the overall accounts receivable turnover cycle of the top 100 pharmaceutical companies was 54.8 days, which was 14.4 days longer than the average level of the national pharmaceutical industry (40.4 days) in the same period. Compared with 2010, the top 100 companies in 2011 The receivables turnover cycle was extended by 10.1 days. The top 100 companies have the advantage of capital scale to a certain extent, and there is no dilemma of capital shortage or shortage. However, how to better shorten the payment return period, realize effective business behaviors, and improve the utilization of capital is the key consideration for companies problem.
In addition, a major feature of the top 100 list is that state-owned enterprises have become a disadvantaged group. Among the top 100 pharmaceutical companies are shareholding companies, Hong Kong, Macao and Taiwan, and foreign-invested economic types. The total value of the two types of companies accounted for 80.71% of the total value of the top 100, which was an increase of 3.42 percentage points from the 2010 level. In 2011, 14 subsidiaries of multinational pharmaceutical companies in China entered the top 100 pharmaceutical companies list, of which 11 were pharmaceutical subsidiaries established in China by Fortune 500 companies.
Tao Jianhong pointed out that in the future, domestic pharmaceutical companies should pay more attention to the changes in the structure of drug demand in order to have new opportunities. According to reports, the future medication structure will generally show several characteristics: one is specialty. With the improvement of the medical insurance level, the medication needs of the elderly and the small population will increase significantly, and it is necessary to develop suitable dosage forms for the elderly and children. Or specifications; the second is compounding, such as the new compound of existing drugs to reduce the frequency of patients' medication, and the emergence of multiple vaccines to prevent multiple diseases, and the emergence of therapeutic vaccines with preventive and therapeutic effects; the third is rationalization, antibiotics The abuse of drugs such as hormones and hormones will be significantly reduced. The use of targeted therapy technologies to reduce the side effects of drugs, pharmacoeconomics guidance prescription analysis, and clinical pharmacy monitoring will be more valued; fourth is defensive, and the prevention of chronic diseases will be highly valued , Some preventive and health-care self-medications will be developed; fifth, stepped, the clinical path of treatment is clearer, and there will be clear stepped medication guidelines for the treatment of chronic diseases, such as hypertension and diabetes; sixth, Personalization, life science promotes the development of genomic research, and it is possible to achieve personalized treatment solutions in the future.